CAI Stock Recent News

Scientific Reports study validates the first multifunctional, AI-enabled blood-based assay to offer diagnostic, prognostic and predictive utility in a single assay. IRVING, Texas , July 8, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced a landmark study published in Scientific Reports, a Nature journal, demonstrating the accuracy and clinical utility of the Caris Assure® blood-based biopsy assay across the cancer continuum.

A handful of IPOs and blank checks priced in the short holiday week, led by two sizable issuers. Two smaller IPOs also priced this past week. One IPO is currently scheduled to list in the week ahead, although some small names may also join the calendar throughout the week.

Caris Life Sciences is experiencing rapid growth, leveraging AI and molecular science for personalized medicine, but remains deeply unprofitable despite narrowing losses. The IPO was strong, with shares surging post-offering and the company now trading at a steep 15-16x sales multiple, reflecting high investor expectations. While revenue growth is impressive and losses are shrinking, the valuation is too rich for my taste, given the ongoing substantial losses and business risks.

Live Updates Live Coverage Has Ended IPO Soars 12:56 pm by Gerelyn Terzo The markets embraced healthcare newcomer Caris Life Sciences (Nasdaq: CAI) today, marking its debut on the Nasdaq. After pricing its initial public offering at $21 per share, Caris Life skyrocketed, rising over 32% to hit $27.85 per share. The company is at the forefront of medical innovation, harnessing AI algorithms in blood tests to diagnose early detection of diseases like breast cancer. The SPY ETF is now up 0.35%. Rising Stocks 11:23 am by Gerelyn Terzo Hasbro (Nasdaq: HAS) shares are up 1.3% today. The toymaker is undertaking a restructuring, resulting in the layoff of 3% of its workforce, a move attributed to the impact of tariffs. Circle (NYSE: CRCL) is surging 16% today, buoyed by the passage of stablecoin-friendly legislation in Congress. Magnificent 7 stock Amazon (Nasdaq: AMZN) is up 0.88% after CEO Andy Jassy projected that artificial intelligence will reshape the corporate workforce in the not-too-d

Live Updates Live Coverage Updates appear automatically as they are published. Today's IPO Receives Warm Welcome 12:53 pm by Gerelyn Terzo The markets rolled out the welcome mat for healthcare stock Caris Life Sciences (Nasdaq: CAI) today, which makes its debut on the Nasdaq. After pricing the IPO at $21 per share, Caris Life has climbed over 32% to $27.85 per share. Caris Life uses AI algorithms in blood tests to diagnose early detection of diseases like breast cancer. The Nasdaq Composite is up 0.47%. Market Gainers 11:17 am by Gerelyn Terzo Hasbro (Nasdaq: HAS) stock is up 1.3% today. The toymaker announced a restructuring in which it is laying off 3% of its workforce due to the impact of the tariffs. Circle (NYSE: CRCL) is soaring 16% today on the heels of stablecoin-friendly legislation that was passed by Congress. Amazon (Nasdaq: AMZN) is up 0.88% today after CEO Andy Jassy forecast that AI would replace more of the corporate workforce in the not-too-distant future as the e-

On Wednesday morning, the cancer diagnostics biotech firm Caris Life Sciences rang Nasdaq's opening bell in New York, marking the company's awaited initial public offering.

Shares of Caris Life Sciences soared in their public debut Wednesday, as investors bought into the company's business of molecular profiling and drug research using artificial intelligence.

The biotechnology company started trading at $27 each on Wednesday afternoon, a day after the company's IPO was priced at $21 a share. The stock was recently up 26% and trading at $26.48.

Caris Life Sciences' shares jumped nearly 29% in their New York debut on Wednesday, fetching the cancer diagnostic firm a valuation of $7.66 billion and signaling a growing investor appetite for new listings in 2025.

David Dean Halbert, Caris Life Sciences chairman, founder and CEO, joins 'Squawk Box' to discuss the company's IPO debut, how the company uses AI technology to help diagnose and treat cancer,